Sentence examples for regulatory view from inspiring English sources

Understanding how size and shape can affect the biodistribution of intravascularly injected particles is of fundamental importance both for the rational design of delivery systems and from a standardization and regulatory view point.

Although the relevance of this issue to patients, as opposed to healthy volunteers, depends on the drug's indication, duration of treatment, and specific findings related to the assays, the regulatory view is to avoid exposing patients to genotoxic compounds unnecessarily in clinical trials.

This regulatory view on decentralization also signals the permanence of certain cryptocurrencies, noting that the field of newly minted tokens and coins is crowded, with more than 1,600 floating around the ether.

The chapters range from an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity.

The role of cell proliferation (CP) in the carcinogenic response is important from a regulatory view in terms of both qualitative and quantitative evidence.

General concern was expressed by the audience about the regulatory view of probiotic food research and how it can be used to substantiate market approval and claims.

Following the tradition of other presidential nominees, Ms. Gall said through an aide that she would not comment on her record or regulatory views while her nomination was pending.

Bank M&A applications are subject to numerous regulatory risks, including preexisting conditions that are unknown or whose importance to the process is underestimated when the deal is signed, changes in the merging parties' businesses, changes in regulatory views or policies, and new regulatory examinations or findings.

Like other emerging areas of biomedical research and development, there are many issues where regulatory views and decisions among countries and regions may differ due to minimal scientific evidence to support safety and efficacy, and lack of experience with these novel treatments.

This view is also reflected in regulatory views on product health claims.

Since regulatory views are changing with respect to the risks and benefits of cell lines (reviewed by Hess et al).